2.695USD-0.55%Mkt Cap: 249.75M USDP/E: —Last update: 2026-05-22
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and r…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap249.75M USD
Enterprise Value119.39M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.38M USD
Revenue/Share—
Last Price2.695 USD
Fiscal Year EndSep 2025
MR QuarterDec 2025
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0327973006
Valuation
P/E (Trailing)—
P/E (Forward)-19.36
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.98
EPS (TTM)-0.46
EPS (Forward)-0.14
52W Range
2.6101% of range13.99
52W High13.99 USD
52W Low2.610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-48.89%
ROA-44.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.04M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-8.74%
Net Debt-131.75M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio20.87
Quick Ratio20.81
Book Value/Sh1.366 USD
Cash/Share1.422 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateOct 7, 2015
Analyst Consensus
Rating—
Target (Mean)22.00 USD
Target Range20.00 USD – 24.00 USD
# Analysts2
Ownership
Shares Out.92.67M
Float89.78M
Insiders3.12%
Institutions43.73%
Short Interest
Short Ratio18.4d
Short % Float21.35%
Short % Out.20.52%
Shares Short19.01M
Short (prev mo.)19.26M
Technical
SMA 503.371 (-20.0%)
SMA 2005.707 (-52.8%)
Beta1.25
S&P 52W Chg28.31%
Avg Vol (30d)975.32K
Avg Vol (10d)1.11M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—